The antinociceptive effect and adverse drug reactions of oxycodone in human experimental pain in relation to genetic variations in the OPRM1 and ABCB1 genes
Corresponding Author
Stine T. Zwisler
Clinical Pharmacology, Institute of Public Health, University of Southern Denmark, Odense, Denmark
Department of Anaesthesiology and Intensive Care, Odense University Hospital, Odense, Denmark
Correspondence and reprints: [email protected]Search for more papers by this authorThomas P. Enggaard
Clinical Pharmacology, Institute of Public Health, University of Southern Denmark, Odense, Denmark
Department of Anaesthesiology and Intensive Care, Odense University Hospital, Odense, Denmark
Search for more papers by this authorLene Noehr-Jensen
Clinical Pharmacology, Institute of Public Health, University of Southern Denmark, Odense, Denmark
Search for more papers by this authorSoeren Mikkelsen
Department of Anaesthesiology and Intensive Care, Odense University Hospital, Odense, Denmark
Search for more papers by this authorCéline Verstuyft
Department of Pharmacology, Faculty of Medicine Paris Sud, University Paris Sud, Paris, France
Search for more papers by this authorLaurent Becquemont
Department of Pharmacology, Faculty of Medicine Paris Sud, University Paris Sud, Paris, France
Search for more papers by this authorSoeren H. Sindrup
Department of Neurology, Odense University Hospital, Odense, Denmark
Search for more papers by this authorKim Brosen
Clinical Pharmacology, Institute of Public Health, University of Southern Denmark, Odense, Denmark
Search for more papers by this authorCorresponding Author
Stine T. Zwisler
Clinical Pharmacology, Institute of Public Health, University of Southern Denmark, Odense, Denmark
Department of Anaesthesiology and Intensive Care, Odense University Hospital, Odense, Denmark
Correspondence and reprints: [email protected]Search for more papers by this authorThomas P. Enggaard
Clinical Pharmacology, Institute of Public Health, University of Southern Denmark, Odense, Denmark
Department of Anaesthesiology and Intensive Care, Odense University Hospital, Odense, Denmark
Search for more papers by this authorLene Noehr-Jensen
Clinical Pharmacology, Institute of Public Health, University of Southern Denmark, Odense, Denmark
Search for more papers by this authorSoeren Mikkelsen
Department of Anaesthesiology and Intensive Care, Odense University Hospital, Odense, Denmark
Search for more papers by this authorCéline Verstuyft
Department of Pharmacology, Faculty of Medicine Paris Sud, University Paris Sud, Paris, France
Search for more papers by this authorLaurent Becquemont
Department of Pharmacology, Faculty of Medicine Paris Sud, University Paris Sud, Paris, France
Search for more papers by this authorSoeren H. Sindrup
Department of Neurology, Odense University Hospital, Odense, Denmark
Search for more papers by this authorKim Brosen
Clinical Pharmacology, Institute of Public Health, University of Southern Denmark, Odense, Denmark
Search for more papers by this authorAbstract
The aim of this study was to search for a possible association between the variant allele of the single nucleotide polymorphisms A118G in the OPRM1 gene and C3435T and G2677T/A in the ABCB1 gene and altered antinociceptive effect and adverse drug reactions of oxycodone. Thirty-three healthy subjects exposed to experimental pain including electrical stimulation and the cold pressor test were included. A118G: We found that the variant G allele was associated with reduced antinociceptive effect as measured by pain tolerance thresholds to single electrical nerve stimulation (8% increase vs. 25% for the wild-type carriers, P = 0.007). C3435T: The carriers of the variant T allele generally had less adverse drug reactions on oxycodone than the carriers of the wild-type genotype. G2677T/A: The carriers of the variant T allele had a better antinociceptive effect of oxycodone than the carriers of the wild-type genotype in the cold pressor test (25% reduction vs. 15%, P = 0.015 in the discomfort rating and 25% reduction vs. 12%, P = 0.007 in the pain time AUC) and less adverse drug reactions. The combined wild-type genotype 3435CC-2677GG was associated with less antinociceptive effect of oxycodone in the discomfort rating of the cold pressor test (13% reduction vs. 23%, P = 0.019) and more severe adverse drug reactions than the carriers of the variant alleles. We found a moderate association between less antinociceptive effect of oxycodone and the variant allele of A118G. There was strong association between less adverse drug reactions of oxycodone and the variant alleles of C3435T and G2677T/A.
References
- 1 Lalovic B., Kharasch E., Hoffer C., Risler L., Liu-Chen L.Y., Shen D.D. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin. Pharmacol. Ther. (2006) 5 461–479.
- 2 Kalso E. Oxycodone. J. Pain Symptom Manage. (2005) 5(Suppl.), S47–S56.
- 3 Riley J., Eisenberg E., Muller-Schwefe G., Drewes A.M., Arendt-Nielsen L. Oxycodone: a review of its use in the management of pain. Curr. Med. Res. Opin. (2008) 1 175–192.
- 4 Hassan H.E., Myers A.L., Lee I.J., Coop A., Eddington N.D. Oxycodone induces overexpression of P-glycoprotein (ABCB1) and affects paclitaxel’s tissue distribution in Sprague Dawley rats. J. Pharm. Sci. (2007) 9 2494–2506.
- 5 Stamer U.M., Stuber F. The pharmacogenetics of analgesia. Expert Opin. Pharmacother. (2007) 14 2235–2245.
- 6 Lotsch J., Skarke C., Grosch S., Darimont J., Schmidt H., Geisslinger G. The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine. Pharmacogenetics (2002) 1 3–9.
- 7 Romberg R.R., Olofsen E., Bijl H. et al. Polymorphism of mu-opioid receptor gene (OPRM1:c.118A>G) does not protect against opioid-induced respiratory depression despite reduced analgesic response. Anesthesiology (2005) 3 522–530.
- 8 Skarke C., Darimont J., Schmidt H., Geisslinger G., Lotsch J. Analgesic effects of morphine and morphine-6-glucuronide in a transcutaneous electrical pain model in healthy volunteers. Clin. Pharmacol. Ther. (2003) 1 107–121.
- 9 Cascorbi I. Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol. Ther. (2006) 2 457–473.
- 10 Ho R.H., Kim R.B. Transporters and drug therapy: implications for drug disposition and disease. Clin. Pharmacol. Ther. (2005) 3 260–277.
- 11
Cascorbi I.,
Gerloff T.,
Johne A.
et al.
Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects.
Clin. Pharmacol. Ther. (2001) 3
169–174.
10.1067/mcp.2001.114164 Google Scholar
- 12 Lotsch J., Skarke C., Geisslinger G. Simultaneous screening for three mutations in the ABCB1 gene. Genomics (2003) 5 503–510.
- 13 Crettol S., Deglon J.J., Besson J. et al. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin. Pharmacol. Ther. (2006) 6 668–681.
- 14 Hoffmeyer S., Burk O., Von R.O. et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. U.S.A. (2000) 7 3473–3478.
- 15 Kadiev E., Patel V., Rad P. et al. Role of pharmacogenetics in variable response to drugs: focus on opioids. Expert Opin. Drug Metab Toxicol. (2008) 1 77–91.
- 16 Johne A., Kopke K., Gerloff T. et al. Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin. Pharmacol. Ther. (2002) 5 584–594.
- 17
Verstuyft C.,
Schwab M.,
Schaeffeler E.
et al.
Digoxin pharmacokinetics and MDR1 genetic polymorphisms.
Eur. J. Clin. Pharmacol. (2003) 12
809–812.
10.1007/s00228-003-0567-5 Google Scholar
- 18 Coller J.K., Barratt D.T., Dahlen K., Loennechen M.H., Somogyi A.A. ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals. Clin. Pharmacol. Ther. (2006) 6 682–690.
- 19 Coulbault L., Beaussier M., Verstuyft C. et al. Environmental and genetic factors associated with morphine response in the postoperative period. Clin. Pharmacol. Ther. (2006) 4 316–324.
- 20 Verstuyft C., Marcellin F., Morand-Joubert L. et al. Absence of association between MDR1 genetic polymorphisms, indinavir pharmacokinetics and response to highly active antiretroviral therapy. AIDS (2005) 18 2127–2131.
- 21 Kim R.B., Leake B.F., Choo E.F. et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin. Pharmacol. Ther. (2001) 2 189–199.
- 22 Zwisler S.T., Enggaard T.P., Noehr-Jensen L. et al. The hypoalgesic effect of oxycodone in human experimental pain models in relation to the CYP2D6 oxidation polymorphism. Basic Clin. Pharmacol. Toxicol. (2009) 4 335–344.
- 23 Pedersen R.S., Damkier P., Brosen K. Tramadol as a new probe for cytochrome P450 2D6 phenotyping: a population study. Clin. Pharmacol. Ther. (2005) 6 458–467.
- 24 Livak K.J. Allelic discrimination using fluorogenic probes and the 5′ nuclease assay. Genet. Anal. (1999) 6 143–149.
- 25 Somogyi A.A., Barratt D.T., Coller J.K. Pharmacogenetics of opioids. Clin. Pharmacol. Ther. (2007) 3 429–444.
- 26 Lotsch J., Geisslinger G. Are mu-opioid receptor polymorphisms important for clinical opioid therapy? Trends Mol. Med. (2005) 2 82–89.
- 27 Kasai S., Hayashida M., Sora I., Ikeda K. Candidate gene polymorphisms predicting individual sensitivity to opioids. Naunyn Schmiedebergs Arch. Pharmacol. (2008) 6 269–281.
- 28 Bostrom E., Hammarlund-Udenaes M., Simonsson U.S. Blood-brain barrier transport helps to explain discrepancies in in vivo potency between oxycodone and morphine. Anesthesiology (2008) 3 495–505.
- 29 Kharasch E.D., Hoffer C., Whittington D., Sheffels P. Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine. Clin. Pharmacol. Ther. (2003) 6 543–554.
- 30 Kharasch E.D., Hoffer C., Altuntas T.G., Whittington D. Quinidine as a probe for the role of p-glycoprotein in the intestinal absorption and clinical effects of fentanyl. J. Clin. Pharmacol. (2004) 3 224–233.
- 31 Kharasch E.D., Hoffer C., Whittington D. The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone. Br. J. Clin. Pharmacol. (2004) 5 600–610.